Nephrology models and services
Uniquely engineered Autosomal Dominant Pkd1 Polycystic Kidney Disease mouse model
Polycystic kidney disease is characterized by the development of renal fluid-filled cysts, eventually leading to kidney failure. With a prevalence of 4 in 10.000, Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a relatively common genetic disorder.
Mutations in the Pkd1 gene are associated with approximately 85% of ADPKD cases. To support the preclinical development of new drugs and therapies for ADPKD, InnoSer offers a validated conditional renal specific Pkd1 knockout mouse model.
Access the data and platform details here
Nephrology research with InnoSer
Powered by ultrasound
In vivo imaging has become a valuable tool for collecting mid study data particularly in long term animal studies. These non-invasive methods can be applied with high sensitivity and in real time. With InnoSer’s imaging capabilities, track your lead compound effects on cyst growth easily. Read more >>
Smart pathological assessment
Histopathological assessments are standard parts of our ADPKD model readouts. Thanks to smart algorithms being trained to identify cysts in an automated manner, these can be offered in an efficient way, also with possibilities of long term and secure cloud storage of the images. Read more >>
Scientific experts to guide you
An expert team of scientists with vast experience in our ADPKD model helps you choose the right model options and set up optimal study designs for your nephrology projects. Curating the preclinical testing of your lead compounds with a deep understanding in the field is your solution to accelarating your drug development.
InnoSer offers different ADPKD mouse models by specifically timed Tamoxifen-induced Pkd1 knockout. There are three models available depending on which post-natal (P) day Tamoxifen is administered:
The P10 model is widely used as a first screening platform as it offers quick and robust results with renal cyst formation, while the P18 and P40 models show a slower progression even closer to clinical phenotypes.
For all your nephrology projects, we support custom in vivo models for kidney injury and toxicological studies.
|P10||Quick progression of cyst formation in the distal segment of the nephron|
|P18||Slow progression with cysts in all segments of the nephron|
|P40||Slow and reproducible cyst formation in the proximal part of the nephron|
Conditional Pkd1 knockout at different time points allows the establishment of multiple mouse models, with different disease progressions and phenotypes to meet your specific requirements in terms of study duration, outcome measures and clinical translatability.
View the list of indications and markers of interest
- Body weight
- Kidney weight
- Ultrasound imaging to determine kidney volume as a long-term non-invasive method for intermediate therapeutic effect evaluation.
- Blood urea evaluation
Histopathology by certified veterinary pathologists:
- Cystic index and associated pathological lesions
- Special stainings and immunohistochemistry for specific markers of interest
Tamoxifen treated kidney in P10 model showing picrosirius red application for collagen quantification
Tamoxifen treated kidney in P18 model showing IHC application targeting Ki67
The people behind the models
Developed by Prof. Dr. Dorien Peters of the LUMC
Dr. Peters from Leiden University Medical Center (LUMC) focuses on insights into the genetic, pathophysiologic and functional mechanisms of inherited disorders.
Laura Blockken , Nephrology Study Director
An expert team of scientists with vast experience in our ADPKD model help you choose the right model and set up your optimal study design. We provide the solution to accelerating your drug development.
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why Innoser has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
Need more information?
If you have any questions about how we can help accelerate your research,
then let us know